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OBJECTIVES The present study was designed to prospectively evaluate the prognostic relevance of
abnormal blood pressure response to exercise (ABPR), defined as hypotension or failed blood
pressure increase (,20 mm Hg) with exercise, in a community-based hypertrophic cardio-
myopathy (HCM) population representative of the overall disease spectrum.
BACKGROUND Abnormal blood pressure response to exercise has been proposed as a marker for hemody-
namic instability and increased risk for disease-related mortality in highly selected patient
populations with HCM.
METHODS The study population comprised 126 patients (aged 42 6 14 years) who underwent maximal
symptom-limited cycloergometer exercise testing as part of the standard evaluation at our
institution, and who were followed systematically for 4.7 6 3.7 years after testing.
RESULTS Of the 126 study patients, 98 (78%) had a normal blood pressure response during exercise,
whereas the other 28 (22%) had ABPR, including nine with hypotension and 19 with failed
blood pressure rise. During the follow-up period, nine patients (7%) died of HCM-related
causes (three suddenly and six heart failure–related), of whom four had ABPR. In those
patients aged #50 years, survival analysis after exercise testing showed a significantly
increased risk for cardiovascular mortality associated with ABPR compared with a normal
exercise response (p 5 0.04), with an odds ratio of 4.5 (95% confidence interval: 1.1, 20.1).
However, ABPR showed low positive predictive accuracy for cardiovascular mortality (i.e.,
14%), whereas negative predictive accuracy was high (i.e., 95%).
CONCLUSIONS A hypotensive blood pressure response during exercise occurred in over 20% of a community-
based patient cohort with HCM, and was associated with adverse long-term prognosis in
patients ,50 years old. However, the positive predictive accuracy of this blood pressure
response is too low to justify modifications of clinical management or to allow identification
of the high-risk patient based solely on an abnormal test result. By virtue of its high negative
predictive accuracy for HCM-related mortality, the blood pressure response to exercise
appears to be most valuable (in conjunction with the absence of other well recognized risk
factors) as a screening test for the identification of low-risk subsets of patients. (J Am Coll
Cardiol 1999;33:2044–51) © 1999 by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM) is a primary cardiac
disease with diverse clinical and genetic expression and
varied clinical course (1–11). Many patients experience
relatively benign course (12–17), whereas others appear to
be at high risk for adverse events and premature death
(18–26). A major challenge in the management of the broad
HCM disease spectrum has been the identification of
subsets of patients predisposed to sudden and unexpected or
heart failure–related death (6,7,22,23). Consequently, the
risk stratification of patient populations with HCM contin-
ues to represent an area of intense investigation, and a
number of disease variables have been proposed as risk
factors associated with adverse prognosis and increased
mortality (2,6–10,20,22–25).
An abnormal systemic blood pressure response to exercise
(ABPR) is among those parameters previously considered as
a potential marker for hemodynamic instability and in-
creased risk (24,27,28), although its clinical significance and
relation to outcome in this disease remains largely unre-
solved. This variable, like virtually all others previously
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proposed for HCM, has been tested exclusively in highly
selected cohorts from tertiary centers comprising HCM
patients referred primarily because they had already been
perceived to be at increased risk (12–17,29). Therefore, we
have assessed the relevance and clinical implications of an
inappropriate blood pressure response to exercise as a risk
factor in a large community-based HCM patient popula-
tion, free of referral bias and therefore more representative
of the true disease state.
METHODS
Patient selection and follow-up. The clinical features and
long-term outcome of HCM in our large cohort of un-
selected, consecutively studied patients assessed longitudi-
nally in a well defined regional population from the Tuscany
region in central Italy have been recently described (14).
Between 1983 and 1995, cycloergometer exercise testing
was administered in our outpatient clinic as part of the
standard evaluation for patients with HCM.
Of the 202 patients in this population, 76 were excluded
from the study for the following reasons: severe exercise
limitation due to congestive symptoms (New York Heart
Association functional class III–IV; n 5 19); refusal to
comply with the protocol (n 5 13); noncardiovascular
physical disabilities incompatible with exercise (e.g., severe
osteoarthrosis or neurologic deficits; n 5 9); age .70 years
(n 5 8); prior documentation of life-threatening arrhyth-
mias (ventricular fibrillation or sustained ventricular tachy-
cardia; n 5 5), and exercise testing performed at other
institutions with different methodology and protocol (n 5
22). Therefore, the final study group comprised 126 patients
(Table 1).
Mean age at the time of the exercise test was 42 6 14
years (range 19 to 68); 89 patients were #50 years old, and
37 patients were .50 years old. Ninety (71%) were male;
121 patients were in sinus rhythm, whereas the remaining
five were in atrial fibrillation. Overall duration of follow-up
from the initial diagnosis of HCM was 9.4 6 6.5 years
(range 1 to 29); the follow-up period after the exercise test
was 4.7 6 3.7 years (range 1 to 13).
The diagnosis of HCM in our study patients was based
on echocardiographic identification of a hypertrophied and
nondilated left ventricle in the absence of another cardiac or
systemic disease capable of producing the magnitude of left
ventricular hypertrophy evident in that patient (30). No
patient identified as having HCM solely in the course of a
systematic pedigree analysis was included in the present
series (10,20,31); however, 18 patients were evaluated after
another relative had become part of the study group. Initial
clinical evaluation was taken as the time the diagnosis of
HCM was first confirmed. The most recent clinical evalu-
ation was obtained in October to December 1995.
Ages at initial evaluation ranged from 1 to 68 years (mean
36 6 15); 15 (12%) were ,20 years, and four (3%) were
.60 years. Ages at the most recent evaluation ranged from
13 to 74 years (mean 47 6 14). After initial identification,
patients were followed in a standard fashion at about
one-year intervals with clinical examination, two-
dimensional echocardiogram, 12-lead electrocardiogram
(ECG) and 24- or 48-h ambulatory (Holter) ECG.
Exercise testing. Patients had cardioactive medications
withdrawn at least five half-lives before the exercise test,
with the exception of the 12 patients receiving amiodarone;
each fasted $4 h before the test. Maximum, symptom-
limited exercise tests were performed on a bicycle ergometer
(Quinton Q 2000, Seattle, Washington) in the upright
position. The same protocol was used with all patients, with
an initial workload of 25 W, stepwise workload increments
of 25 W every 3 min and a recovery phase comprising 3 min
against a workload of 25 W followed by another 3 min at
0 W. Three leads were monitored in a continuous fashion
(D2, V2 and V5); in addition, a 12-lead ECG was recorded
at baseline, and at each minute during exercise and the
recovery phase. Blood pressure was measured using a mer-
cury sphygmomanometer at baseline, at 60 and 150 s of each
step, and every minute during the recovery phase. Maxi-
mum predicted heart rate and workload for each patient was
calculated with respect to age, gender, height and weight
(32). Percent of functional capacity was calculated as:
(maximum workload performed/maximum predicted work-
load) 3 100.
An abnormal blood pressure response to exercise was
defined as follows: 1) exercise-induced hypotension; any
decrease in systolic blood pressure below baseline values
occurring during the exercise phase or recovery in the
absence of an initial rise with exercise, or alternatively a
sustained (.1 min in duration) decrease of $20 mm Hg
during exercise after an initial rise, and 2) failure to increase
blood pressure with exercise, defined as a systolic blood
pressure rise of less than 20 mm Hg from baseline during
exercise.
Echocardiography. Echocardiographic studies were per-
formed using commercially available instruments (Toshiba
65A and 270) and 3.5- or 5.0-mHz transducers. Extent and
distribution of left ventricular hypertrophy was assessed
from the two-dimensional echocardiogram as previously
described (33,34). Magnitude of the peak instantaneous left
ventricular outflow tract gradient under basal conditions was
estimated with continuous wave Doppler (35). Significant
left ventricular outflow tract obstruction was considered
present when the peak instantaneous gradient was
$30 mm Hg.
Abbreviations and Acronyms
ABPR 5 abnormal blood pressure response to exercise
ECG 5 electrocardiogram
HCM 5 hypertrophic cardiomyopathy
2045JACC Vol. 33, No. 7, 1999 Olivotto et al.
June 1999:2044–51 BP Response to Exercise in HCM
Statistical analysis. Data were expressed as mean 6 stan-
dard deviation. Statistical analyses were performed using
unpaired Student t test for the comparison of normally
distributed data. Chi-square test was used to compare
noncontinuous variables expressed as proportions. Univari-
ate analyses for survival curves were calculated using
Kaplan-Meier estimates (36). Univariate and multivariate
regression analysis, for the identification of independent
predictors of HCM-related death, were performed by the
Cox regression model (37), using a SPSS statistical package
(SPSS, Chicago, Illinois). The multivariate analysis used the
forced entry method, and only included those demographic,
clinical and echocardiographic variables that were signifi-
cantly associated with HCM-related mortality at univariate
analysis.
RESULTS
Exercise testing. The 126 study patients exercised for 12 6
4 min (range 2 to 25), reaching maximum workloads
varying from 25 to 225 W; percent of maximum predicted
heart rate achieved was 87 6 14%; mean percent of
predicted functional capacity was 75 6 23% (Table 1).
Reasons for termination of the test were as follows: fatigue
(67 patients; 53%), dyspnea (26 patients; 21%), chest pain
(21 patients; 16%), symptomatic hypotension (7 patients;
Table 1. Demographic, Clinical and Exercise Testing Parameters in 126 Patients With Hypertrophic Cardiomyopathy
Systemic BP Response to Exercise
Abnormal (ABPR)* Normal Overall Population
n % p Value† n % n %
Number of patients 28 98 126
Male* 14 50 , 0.005 76 78 90 71
Age (yr)* 37 6 16 — , 0.05 44 6 13 — 42 6 14
Family history HCM* 14 50 NS 37 38 51 40
Family history of premature HCM death* 5 18 NS 9 9 14 11
Basal outflow obstruction (.30 mm Hg)*‡ 9 32 NS 18 18 27 21
NSVT on Holter ECG* 13 46 NS 36 37 49 39
Hx of syncope* 5 18 NS 11 11 16 13
Hx of chest pain* 15 54 , 0.05 27 28 42 33
Hx of dyspnea* 14 50 NS 45 46 59 47
Hx of atrial fibrillation* 3 11 NS 11 11 14 11
Left atrial dimension (mm)* 42 6 8 — NS 39 6 7 — 40 6 7 —
LV end-diastolic dimension (mm) 41 6 6 — , 0.05 44 6 6 — 43 6 6 —
% fractional shortening* 38 6 7 — NS 39 6 7 — 39 6 8 —
Max. LV thickness (mm)* 22 6 6 — NS 23 6 6 — 23 6 6 —
Medical treatment at time of exercise test§ 18 64 NS 48 49 66 52
Amiodarone* 4 14 NS 8 8 12 10
Beta-blockers* 11 39 NS 22 22 33 26
Verapamil/diltiazem* 5 18 NS 13 13 18 6
Nifedipine 0 0 NS 5 5 5 4
ACE inhibitors/diuretics 5 18 NS 11 11 16 13
Exercise testing
Duration of exercise (min)* 9 6 3 — , 0.001 13 6 4 — 12 6 4 —
Chest pain 7 25 NS 14 15 21 17
Dyspnea 7 25 NS 15 15 22 17
Basal heart rate (bpm) 72 6 11 — NS 76 6 15 — 75 6 15 —
Max. heart rate (bpm) 140 6 34 — , 0.05 157 6 25 — 153 6 28 —
% max. predicted heart rate 78 6 17 — , 0.005 90 6 12 — 87 6 14 —
Basal systolic BP (mm Hg) 119 6 20 — NS 125 6 15 — 124 6 16 —
Max. systolic BP (mm Hg) 138 6 21 — , 0.001 184 6 30 — 174 6 34 —
Basal diastolic BP (mm Hg) 77 6 11 — , 0.05 82 6 10 — 81 6 10 —
Max. diastolic BP (mm Hg) 83 6 10 — , 0.001 92 6 12 — 90 6 13 —
Basal double product 8,126 6 1,743 — , 0.005 9,569 6 2,371 — 9,248 6 5,040 —
Max. double product* 19,491 6 6,013 — , 0.001 29,188 6 6,859 — 27,033 6 7,791 —
% predicted functional capacity* 62 6 27 — , 0.001 79 6 20 — 75 6 23 —
*Variable included in the univariate analysis for HCM-related mortality. †Comparisons between subgroups with and without ABPR. ‡Estimated with continuous wave Doppler
echocardiography (35). §All cardioactive medications were withdrawn at least five half-lives before the test, with the exception of amiodarone.
ABPR 5 abnormal blood pressure response to exercise; ACE 5 angiotensin-converting enzyme; BP 5 blood pressure; ECG 5 electrocardiogram; HCM 5 hypertrophic
cardiomyopathy; Hx 5 history; LV 5 left ventricle; Max. 5 maximum; NSVT 5 nonsustained ventricular tachycardia; — 5 data nonapplicable.
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6%) and arrhythmias (5 patients; 4%). In 104 patients,
$75% of the predicted maximal heart rate value was
achieved during exercise, whereas in the other 22 patients
testing was terminated before such levels could be achieved.
Complete exercise test results for the study group are shown
in Table 1.
During the exercise test, 33 patients (26%) had arrhyth-
mias, including 29 with multiple ventricular premature
beats, 2 with paroxysmal atrial fibrillation and 1 each with
nonsustained ventricular tachycardia or nonsustained su-
praventricular tachycardia. In four patients exercise testing
elicited rate-dependent conduction defects (complete or
incomplete left bundle branch block) that had been absent
at rest, whereas 23 others had ST-segment and T-wave
alterations, including 16 patients in whom ST-segment
depression suggested myocardial ischemia (i.e., $2 mm).
Systemic blood pressure response to exercise. Of the 126
patients, 98 (78%) showed normal blood pressure increase
during the exercise test (mean 60 6 25 mm Hg; range 25 to
110) (Table 1). The remaining 28 (22%) had an ABPR,
including 19 patients in whom blood pressure failed to
increase appropriately (maximum increase 10 6 6 mm Hg;
range 5 to 18), and nine others with hypotension (maximum
blood pressure drop 28 6 6 mm Hg; range 220 to 235); six
of these nine had an initial blood pressure rise followed by
subsequent drop $20 mm Hg, whereas the other three had
blood pressure drop below baseline values in the absence of
an initial rise (Fig. 1; Table 2). Patients with ABPR more
frequently experienced dizziness during the exercise test
than patients with a normal blood pressure response (25%
vs. 2%, p , 0.001; Table 1), but there were no other
significant differences between the two groups with regard
to the occurrence of symptoms and arrhythmias (Table 1).
Compared with patients with normal blood pressure
response, the 28 patients with ABPR achieved a lesser
degree of cardiovascular stress as judged by maximum heart
rate and double product values (Table 1). Patients with
ABPR were also younger and more often female, had
smaller left ventricular end-diastolic dimension and more
often experienced chest pain unrelated to exercise testing.
The patient subgroups with and without ABPR did not
differ in terms of the frequency of drug treatment with
amiodarone, beta-adrenergic blocking agents, calcium chan-
nel antagonists, angiotensin-converting enzyme inhibitors
or diuretics during the follow-up period (Table 1).
Peak systolic left ventricular outflow tract gradient
($30 mm Hg; range 30 to 110 mm Hg) measured by
Doppler echocardiography under basal conditions before
exercise testing was present in 26 of the 126 study patients.
Outflow gradients $30 mm Hg were present with similar
frequency in patients with ABPR (9/28; 32%) and those
with normal pressure response to exercise (18/98; 18%; p 5
NS) (Table 1). Average outflow tract gradient was also
similar in the two patient subgroups (28 6 34 mm Hg with
ABPR vs. 32 6 26 mm Hg without ABPR; p 5 NS).
Cardiovascular mortality and predictive value of abnor-
mal blood pressure response. During the follow-up pe-
riod, nine patients died of HCM-related causes, at 17 to 69
years of age (mean 43 6 18). Duration of time between the
exercise test and death was 5.6 6 3.1 years (range, 5 months
to 8 years). Of the 9 HCM-related deaths, six were
primarily heart failure–related and three were sudden and
unexpected. Of the 6 patients who died of heart failure, 2
had ABPR (one with hypotension and one with failure to
appropriately increase blood pressure). Three patients died
suddenly, each before the age of 30; two of these patients
had ABPR, manifested by symptomatic exercise-induced
hypotension in both cases (Table 1; Fig. 1). Therefore, of
the 9 patients with HCM-related death, a total of 4 (44%)
had ABPR.
Of the other 117 surviving patients, a total of 24 (20%)
had ABPR, of whom six had exercise-induced hypotension
and 18 failed to appropriately increase blood pressure. The
negative predictive accuracy of ABPR for cardiovascular
mortality was 95% and positive predictive accuracy was 14%.
In the subset of patients aged 50 or less at the time of the
exercise test (n 5 89), Kaplan-Meier survival analysis
showed an increased risk for HCM-related mortality in
patients with ABPR as compared with those patients with a
normal blood pressure response to exercise (p 5 0.04; Fig.
2). Conversely, in those patients .50 years of age (n 5 37),
ABPR was not associated with an increased risk for cardio-
vascular mortality (p 5 0.4). Only one of the nine HCM-
related deaths occurred among patients .50 years of age (in
a 68-year-old man with a normal blood pressure response
during exercise), whereas the remaining eight deaths oc-
curred among patients #50 years. The two subgroups of
patients, aged .50 years and #50 years at the time of the
exercise test, had a similar prevalence of ABPR (24% vs.
19%, respectively; p 5 NS), and comparable follow-up
Figure 1. Diagram showing systolic blood pressure (BP) and heart
rate responses during exercise and the recovery phase in a severely
symptomatic 16-year old girl with nonobstructive hypertrophic
cardiomyopathy (patient #1 in Table 2). Systolic blood pressure
failed to increase from the baseline value of 100 mm Hg, and the
test was interrupted after 2 min and 30 s due to hypotension
(baseline systolic blood pressure of 100 mm Hg dropping abruptly
to 80 mm Hg) associated with dizziness. This patient died
suddenly and unexpectedly six months after the exercise test.
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duration (4.5 6 3.6 years vs. 3.7 6 2.9 years, respectively;
p 5 NS).
Univariate regression analysis showed only ABPR, age,
history of syncope and atrial fibrillation, out of 20 demo-
graphic, clinical and echocardiographic features (Table 1),
to be significantly associated with HCM-related mortality
in patients #50 years of age. Of these four variables, the
only independent predictors of risk at multivariate analysis
were ABPR (p 5 0.04; odds ratio 5 4.5; 95% confidence
interval: 1.1, 20.1) and atrial fibrillation (p 5 0.03; odds
ratio 5 5.4; 95% confidence interval: 1.1, 7.5). For those
patients #50 years of age, negative predictive accuracy of
ABPR for cardiovascular mortality was 94% and positive
predictive accuracy was 19%. The presence of nonsustained
ventricular tachycardia on Holter ECG monitoring was not
significantly associated with HCM-related mortality in our
study population at univariate analysis (p 5 0.4), and
therefore was not included in the multivariate model.
DISCUSSION
Risk stratification in HCM. Sudden and unexpected
death, the most devastating feature of the natural history of
HCM, is a relatively uncommon event, but may constitute
the first clinical manifestation of the disease in previously
asymptomatic patients (1–7,18,19,22–26). Despite exten-
sive efforts over three decades, the assessment of high (and
low) risk in individual patients with HCM remains largely
unresolved (6,7) due to the relatively low prevalence of the
disease, extreme heterogeneity and complex pathophysiol-
ogy characteristic of the disease, as well as the severe degree
to which tertiary center patient referral bias has dominated
the HCM literature and has skewed our perceptions of this
condition (6,7,29). A hypotensive blood pressure response
to exercise has been regarded as evidence for hemodynamic
instability and proposed as a marker of increased risk for
adverse cardiovascular events and mortality, both in coro-
nary artery disease (38–41) and in selected tertiary center
patient populations with HCM (24,27,28). For these rea-
sons, we have investigated the clinical implications of the
systemic blood pressure response to exercise in a large
community-based HCM cohort in which the selection of
patients was not biased by the preferential referral of those
already judged to be at high risk.
Prevalence of ABPR. In our community-based outpatient
population, exercise testing was administered as a part of a
standard noninvasive evaluation of patients with HCM. Of
the 126 patients in the study group, about 20% showed an
ABPR that included the development of hypotension or the
failure to appropriately increase blood pressure with exer-
cise. The prevalence of ABPR in the present study patients
was similar, although somewhat lower, than that previously
reported by Frenneaux et al. (28) (i.e., 22% vs. 33%). These
differences may be explained by the fact that the latter study
used treadmill exercise testing (rather than cycloergometer)
and probably comprised higher risk patients. Compared
with those patients with a normal blood pressure response to
exercise, patients with ABPR were also younger, more often
experienced chest pain, had smaller left ventricular cavity
size, and reached a lower degree of cardiovascular stress, as
judged by the maximum double product achieved.
Hypertrophic cardiomyopathy–related mortality and
ABPR. In our study, ABPR was associated with HCM-
related death in patients #50 years, at the time of the
exercise test, but was not a predictor of mortality in those
patients .50 years. Among our study patients, only one of
the nine HCM-related deaths occurred in patients .50
years of age, consistent with reports that HCM diagnosed
later in life is usually associated with a benign prognosis
(6,7). Thus, the survival analysis in the present study
specifically describes that subset of HCM patients for whom
risk stratification is most appropriate, that is, those #50
years. In the follow-up period subsequent to the exercise
test, patients aged #50 years with ABPR showed a fourfold
increase in premature HCM-related cardiovascular mortal-
ity (either suddenly or due to heart failure), compared with
those with a normal blood pressure rise. However, the
positive predictive accuracy of ABPR for mortality was low
(i.e., 14%). This lack of predictability appears in large
measure to be a consequence of the relatively uncommon
occurrence of HCM-related death in our cohort, as reflected
by the wide confidence interval evident in the multivariate
survival analysis. Moreover, the uncertain significance of
ABPR as a marker for the subsequent occurrence of clinical
events is underlined by the fact that of the three patients in
our study population who ultimately died suddenly, none
collapsed during or just after exercise. Consequently, al-
though we established a relationship between ABPR and
increased cardiovascular mortality in patients #50 years of
age, the positive predictive value of this single test is itself
too low to allow identification of the high risk patient or
modify clinical decision making. These observations sub-
stantiate the prior difficulties, shared by many authors, in
Figure 2. Cumulative survival measured from the time of the
maximal symptom-limited exercise test in 89 hypertrophic cardio-
myopathy patients aged #50 years. The 21 patients who demon-
strated abnormal systemic blood pressure response to exercise
(ABPR; broken line) showed significantly reduced survival com-
pared with the 68 patients with a normal blood pressure (BP)
response (solid line), over an average follow-up period of 4.7 6 3.7
years.
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defining subgroups of high risk HCM patients (2,6–
10,20,22–25).
Identification of low risk patients. Conversely, ABPR
showed a negative predictive accuracy of 95% for HCM-
related mortality. This finding has important clinical impli-
cations because a normal blood pressure response during
exercise testing appears to reliably identify those patients at
lower risk. Therefore, as with other tests that have been
proposed for risk stratification in patients with HCM (such
as Holter ambulatory ECG) (23,25), assessment of the
blood pressure response to exercise appears to be most useful
as a screening study and an aid in identifying low risk
subsets of HCM patients; indeed, such individuals are
probably most patients within the overall HCM population
(6). In this regard, a normal blood pressure response to
exercise associated with the absence of certain acknowledged
risk factors—previous cardiac arrest or sustained ventricular
tachycardia, family history of multiple sudden or other
HCM-related deaths and malignant genotype, multiple-
repetitive or prolonged bursts of nonsustained ventricular
tachycardia on ambulatory Holter ECG, recurrent syncope
and probably massive left ventricular hypertrophy (wall
thickness $35 mm)—would appear to define those patients
at low risk for an adverse clinical event, as suggested by
Spirito et al. (6). Such patients probably do not require
further aggressive diagnostic or therapeutic interventions
and benefit most from reassurance regarding their prognosis
(6,7).
Mechanisms and study limitations. The different prog-
nostic implications of ABPR in HCM patients .50 years
and #50 years may be the consequence of diverse underly-
ing mechanisms in the two age groups. In younger patients,
ABPR may reflect hemodynamic instability and thus
suggest risk for a sudden cardiac event; however, in older
patients, ABPR may simply reflect age-related cardiovascu-
lar changes which have little prognostic relevance. The
mechanisms that may explain the abnormal pressure re-
sponse to exercise in younger patients with HCM include:
1) impaired left ventricular filling secondary to tachycardia,
associated with an inability to maintain an adequate stroke
volume; or 2) an exaggerated fall in peripheral vascular
resistance related to an abnormal ventricular mechanoceptor
reflex, resulting in an inhibition of sympathetic tone in
resistance vessels (28).
Exercise testing conducted in this large study population
was used primarily as part of the clinical evaluation in an
outpatient setting. Therefore, invasive hemodynamic mea-
surements were impractical for our study patients, prohib-
iting a direct assessment of peripheral vascular resistance,
cardiac output and consequently the precise physiologic
mechanisms responsible for ABPR. A second limitation
results from the small number of sudden cardiac deaths that
occurred during the follow-up period. This low event rate
probably reflects the relatively benign prognosis of HCM in
our community-based cohort, as well as the administration
of amiodarone to a sizeable subset of our patients. As a
consequence, although ABPR proved to be an independent
risk factor for combined sudden and heart failure-related
HCM deaths in patients #50 years of age, we could not
assess the prognostic significance of ABPR with regard to
sudden and unexpected death alone.
Reprint requests and correspondence: Dr. Barry J. Maron, 920
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